Clinical Trials Directory

Trials / Unknown

UnknownNCT05531227

Corticosteroid Therapy for Persistent Synovitis in Acute Septic Arthritis on Native Joint

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
University Hospital, Strasbourg, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Acute septic arthritis is a rare but life-threatening and functionally serious disease. The improvement or disappearance of pain and functional recovery are sometimes difficult to obtain, with in some cases the persistence of synovitis due to a prolonged local inflammatory response, despite early and effective treatment. The consequences are significant for patients with often significant chronic pain, repercussions on autonomy and/or profession. An unfavorable evolution with joint destruction and need for replacement by a prosthesis is not uncommon. Corticosteroid therapy is widely used in rheumatology in similar tables, for the purpose of drug synovectomy, with good results. The risk of infection remains the main contraindication to its use. There are very few studies on its use in septic arthritis, either fundamentally or in humans, for which there are no data in adults. However, these have shown results encouraging the investigators not to neglect this therapy.

Conditions

Timeline

Start date
2022-06-20
Primary completion
2023-12-13
Completion
2023-12-13
First posted
2022-09-07
Last updated
2023-05-11

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05531227. Inclusion in this directory is not an endorsement.

Corticosteroid Therapy for Persistent Synovitis in Acute Septic Arthritis on Native Joint (NCT05531227) · Clinical Trials Directory